We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+48.87%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$222M
AUM Growth
+$67.9M
Cap. Flow
+$2.82M
Cap. Flow %
1.27%
Top 10 Hldgs %
99.5%
Holding
14
New
1
Increased
1
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$34.3M
2
IMA
ImageneBio Inc
IMA
+$3.55M

Top Sells

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$11M
2
UPB
Upstream Bio Inc
UPB
+$10.6M
3
NUVB icon
Nuvation Bio
NUVB
+$6.03M
4
LXEO icon
Lexeo Therapeutics
LXEO
+$4.76M
5
IMUX icon
Immunic
IMUX
+$1.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KMTS
1
Kestra Medical Technologies
KMTS
$1.23B
$39.1M 17.59%
1,645,893
– –
BBNX
2
Beta Bionics
BBNX
$706M
$38.2M 17.16%
1,920,125
-68,162
-3% -$1.2M
BBOT
3
BridgeBio Oncology
BBOT
$707M
$38.1M 17.13%
+3,289,661
New +$34.3M
BCAX
4
Bicara Therapeutics
BCAX
$1.78B
$34.8M 15.66%
2,204,650
– –
NUVB icon
5
Nuvation Bio
NUVB
$2.24B
$32.7M 14.69%
8,831,089
-2,211,639
-20% -$6.03M
UPB
6
Upstream Bio Inc
UPB
$349M
$25.5M 11.47%
1,356,293
-680,000
-33% -$10.6M
IMA
7
ImageneBio Inc
IMA
$63.1M
$3.71M 1.67%
455,361
+267,934
+143% +$3.55M
ENGN icon
8
enGene Therapeutics
ENGN
$122M
$3.6M 1.62%
526,357
– –
SANA icon
9
Sana Biotechnology
SANA
$885M
$3M 1.35%
843,750
– –
ALMS
10
Alumis Inc
ALMS
$3.57B
$2.61M 1.17%
653,223
– –
REPL icon
11
Replimune Group
REPL
$814M
$1.04M 0.47%
248,672
-1,726,531
-87% -$11M
ENGNW icon
12
enGene Therapeutics Warrants
ENGNW
$3.75M
$63.4K 0.03%
89,702
-231,800
-72% -$176K
IMUX icon
13
Immunic
IMUX
$182M
– –
-178,816
Closed -$1.25M
LXEO icon
14
Lexeo Therapeutics
LXEO
$366M
– –
-1,184,636
Closed -$4.76M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2025 Portfolio in Review

As of Q3 2025, Omega Fund Management held 14 positions worth $222M, up 44% from $154M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management's Q3 2025 filing shows 1 new, 1 increased, 5 reduced and 2 closed positions. Its largest new stake was BridgeBio Oncology: 3,289,661 shares worth $38.1M. The largest sale was Replimune Group, an estimated $11M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Omega Fund Management's largest Q3 2025 buy was BridgeBio Oncology: 3,289,661 shares worth $38.1M.
  • Omega Fund Management added most to ImageneBio Inc in Q3 2025, an estimated $3.55M increase.
  • Omega Fund Management's biggest Q3 2025 reduction was Replimune Group, cutting an estimated $11M.
  • Omega Fund Management fully exited Lexeo Therapeutics in Q3 2025, selling an estimated $4.76M.
  • Omega Fund Management's ten largest holdings make up 100% of its $222M portfolio in Q3 2025.
  • Omega Fund Management opened 1 new position and closed 2 in Q3 2025.
  • Omega Fund Management's portfolio value rose 44% quarter-over-quarter to $222M.

Based on Omega Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.